Therapeutics
Peptide therapeutics, area by area
Each hub covers the underlying biology, the strength and limits of the clinical evidence, and the regulatory picture. Clinical use is described to explain practice, never as guidance.
Therapeutic hub
Metabolic Peptides
Incretin-based medicines are the most heavily evidenced peptide class in modern metabolic medicine — and the most heavily counterfeited.
Therapeutic hub
Endocrine Peptides
Growth hormone axis peptides, releasing hormones, and secretagogues — an area where approved indications are narrow and off-label promotion is common.
Therapeutic hub
Bone Health Peptides
Parathyroid hormone analogues and related anabolic agents represent one of the clearest examples of peptide medicines with defined, evidence-backed indications.
Therapeutic hub
Cardiovascular Peptides
Natriuretic peptide biology underpins both diagnostics and therapeutics, with a development history that illustrates how hard cardiovascular endpoints are to move.
Therapeutic hub
Oncology-Related Peptides
Peptide receptor radionuclide therapy, hormone-axis suppression, and peptide-drug conjugates — high-stakes clinical medicine with strict oversight.
Therapeutic hub
Neurology-Related Peptides
From CGRP-targeting migraine therapies to early work on neurodegeneration, delivery across the blood-brain barrier defines what is feasible.
Editorial disclaimer
This site is educational and does not provide medical advice, dosing protocols, or treatment recommendations. Regulatory status and evidence strength differ sharply between compounds. A “research use only” label does not indicate that a product is appropriate for human use. Decisions about medicines belong with a qualified clinician.